Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy

F. M. Russell; P. V. Licciardi; A. Balloch; V. Biaukula; L. Tikoduadua; J. R. Carapetis; J. Nelson; A. W.J. Jenney; L. Waqatakirewa; S. Colquhoun; Y. B. Cheung; M. L.K. Tang; E. K. Mulholland

doi:10.1016/j.vaccine.2010.02.065

Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy

F. M. Russell^*, P. V. Licciardi, A. Balloch, V. Biaukula, L. Tikoduadua, J. R. Carapetis, J. Nelson, A. W.J. Jenney, L. Waqatakirewa, S. Colquhoun, Y. B. Cheung, M. L.K. Tang, E. K. Mulholland

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

29 Citations (Scopus)

Abstract

Fijian infants aged 6 weeks were stratified by ethnicity and randomized to receive 0, 1, 2, or 3 PCV-7 doses with or without the 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months. Strong booster effects for all 7 PCV-7 serotypes were elicited, and for 4/7 serotypes these responses were highest in the single PCV-7 group. There were fourfold rises in GMC for all non-PCV-7 serotypes. By 17 months the PPV-23 group still had significantly higher GMC (each p < 0.001) for all serotypes. The PPV-23 was well tolerated and induced excellent responses for all serotypes which were greatest in the single PCV-7 group.

Original language	English
Pages (from-to)	3086-3094
Number of pages	9
Journal	Vaccine
Volume	28
Issue number	18
DOIs	https://doi.org/10.1016/j.vaccine.2010.02.065
Publication status	Published - 19 Apr 2010
Externally published	Yes

Access to Document

10.1016/j.vaccine.2010.02.065

Cite this

Russell, F. M., Licciardi, P. V., Balloch, A., Biaukula, V., Tikoduadua, L., Carapetis, J. R., Nelson, J., Jenney, A. W. J., Waqatakirewa, L., Colquhoun, S., Cheung, Y. B., Tang, M. L. K., & Mulholland, E. K. (2010). Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy. Vaccine, 28(18), 3086-3094. https://doi.org/10.1016/j.vaccine.2010.02.065

@article{f4b6e6a1ef0d47988c261376d77b69f6,

title = "Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy",

abstract = "Fijian infants aged 6 weeks were stratified by ethnicity and randomized to receive 0, 1, 2, or 3 PCV-7 doses with or without the 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months. Strong booster effects for all 7 PCV-7 serotypes were elicited, and for 4/7 serotypes these responses were highest in the single PCV-7 group. There were fourfold rises in GMC for all non-PCV-7 serotypes. By 17 months the PPV-23 group still had significantly higher GMC (each p < 0.001) for all serotypes. The PPV-23 was well tolerated and induced excellent responses for all serotypes which were greatest in the single PCV-7 group.",

keywords = "Booster, Pneumococcal, Polysaccharide",

author = "Russell, \{F. M.\} and Licciardi, \{P. V.\} and A. Balloch and V. Biaukula and L. Tikoduadua and Carapetis, \{J. R.\} and J. Nelson and Jenney, \{A. W.J.\} and L. Waqatakirewa and S. Colquhoun and Cheung, \{Y. B.\} and Tang, \{M. L.K.\} and Mulholland, \{E. K.\}",

year = "2010",

month = apr,

day = "19",

doi = "10.1016/j.vaccine.2010.02.065",

language = "English",

volume = "28",

pages = "3086--3094",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "18",

}

Russell, FM, Licciardi, PV, Balloch, A, Biaukula, V, Tikoduadua, L, Carapetis, JR, Nelson, J, Jenney, AWJ, Waqatakirewa, L, Colquhoun, S, Cheung, YB, Tang, MLK & Mulholland, EK 2010, 'Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy', Vaccine, vol. 28, no. 18, pp. 3086-3094. https://doi.org/10.1016/j.vaccine.2010.02.065

Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy. / Russell, F. M.; Licciardi, P. V.; Balloch, A. et al.
In: Vaccine, Vol. 28, No. 18, 19.04.2010, p. 3086-3094.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy

AU - Russell, F. M.

AU - Licciardi, P. V.

AU - Balloch, A.

AU - Biaukula, V.

AU - Tikoduadua, L.

AU - Carapetis, J. R.

AU - Nelson, J.

AU - Jenney, A. W.J.

AU - Waqatakirewa, L.

AU - Colquhoun, S.

AU - Cheung, Y. B.

AU - Tang, M. L.K.

AU - Mulholland, E. K.

PY - 2010/4/19

Y1 - 2010/4/19

N2 - Fijian infants aged 6 weeks were stratified by ethnicity and randomized to receive 0, 1, 2, or 3 PCV-7 doses with or without the 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months. Strong booster effects for all 7 PCV-7 serotypes were elicited, and for 4/7 serotypes these responses were highest in the single PCV-7 group. There were fourfold rises in GMC for all non-PCV-7 serotypes. By 17 months the PPV-23 group still had significantly higher GMC (each p < 0.001) for all serotypes. The PPV-23 was well tolerated and induced excellent responses for all serotypes which were greatest in the single PCV-7 group.

AB - Fijian infants aged 6 weeks were stratified by ethnicity and randomized to receive 0, 1, 2, or 3 PCV-7 doses with or without the 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months. Strong booster effects for all 7 PCV-7 serotypes were elicited, and for 4/7 serotypes these responses were highest in the single PCV-7 group. There were fourfold rises in GMC for all non-PCV-7 serotypes. By 17 months the PPV-23 group still had significantly higher GMC (each p < 0.001) for all serotypes. The PPV-23 was well tolerated and induced excellent responses for all serotypes which were greatest in the single PCV-7 group.

KW - Booster

KW - Pneumococcal

KW - Polysaccharide

UR - https://www.scopus.com/pages/publications/77949659630

U2 - 10.1016/j.vaccine.2010.02.065

DO - 10.1016/j.vaccine.2010.02.065

M3 - Article

SN - 0264-410X

VL - 28

SP - 3086

EP - 3094

JO - Vaccine

JF - Vaccine

IS - 18

ER -

Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy

Abstract

Access to Document

Other files and links

Fingerprint

Cite this